Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. - Wikidata - awgldk - TriplyDB

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

http://www.wikidata.org/entity/Q45879717

about

Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond The complex molecular biology of amyotrophic lateral sclerosis (ALS)Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALS A small molecule p75(NTR) ligand protects neurogenesis after traumatic brain injury Vascular endothelial growth factor protects post-ganglionic sympathetic neurones from the detrimental effects of hydrogen peroxide by increasing catalase Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders Computational modeling of interacting VEGF and soluble VEGF receptor concentration gradients.Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo.Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord.Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis.Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury Downregulation of genes with a function in axon outgrowth and synapse formation in motor neurones of the VEGFdelta/delta mouse model of amyotrophic lateral sclerosis.Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.Human motor neurons generated from neural stem cells delay clinical onset and prolong life in ALS mouse model Schwann-like cells seeded in acellular nerve grafts improve nerve regeneration.Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.Transplantation of ciliary neurotrophic factor-expressing adult oligodendrocyte precursor cells promotes remyelination and functional recovery after spinal cord injury.Modelling amyotrophic lateral sclerosis: progress and possibilities Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration.VEGF-A and Semaphorin3A: modulators of vascular sympathetic innervation.Measures of bulbar and spinal motor function, muscle innervation, and mitochondrial function in ALS rats.Sustained delivery of VEGF maintains innervation and promotes reperfusion in ischemic skeletal muscles via NGF/GDNF signaling Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system.The potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosis Moderate exercise delays the motor performance decline in a transgenic model of ALS.Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

P2860

Q22241945-7D52E18E-7FE8-4135-9EC6-0C23FB731FD9 Q24655277-10E35D90-BAD2-45A1-B109-2EE742CD2477 Q26999881-DE67EE94-C23D-4C86-B16E-5C5E68996B5F Q27004077-7A735B97-19FD-43C2-84D3-AF96BC5C26AC Q28260984-1D8AD90F-E10E-4D3C-8EBC-8D2D3AE96214 Q28263899-8D914B92-B513-4245-B2C6-7E728648E87D Q28269380-49C6BCA2-D9EE-4815-AE79-61ED5EB25A00 Q28285156-C3F31AA0-A75A-49A2-924D-12856593530B Q28392297-D88487A4-1B22-4800-B533-760CE739A8A3 Q28393678-287C07C5-3AF2-4706-91A2-58EDD305647C Q28568991-BE8C88DB-5EE4-4700-8D55-1AC7BBF5881A Q28572195-575D3EDE-B68C-4513-A303-8C28E1C2E834 Q28583917-F94692E2-2C7B-4386-905A-85FBFA8E8B3B Q28740407-D458CE61-7DA5-4911-A3A6-B35BC1606B33 Q29615839-71F1D626-EEA8-41DB-9EF0-6616EF3696C4 Q30430268-26579E41-18F6-441E-86E6-97E95D2613F3 Q30499862-0C6C1599-C2EF-4F99-916A-8E54F99A2769 Q31111228-74B66DF1-9D86-4D98-92FB-7CE84474CD05 Q33273600-2B26A8C0-1440-4487-82B9-85C6D2B27E90 Q33282666-80F14770-E5CF-4AEE-9044-395F5D435FAA Q33421738-9A673696-78FD-46BB-810B-1B416D3B941A Q33546654-90A3AFF6-B461-4F9A-AC70-87E508C9EC9E Q33584304-B0792392-A88D-40C4-9641-7C40C8415068 Q33616384-5FD16877-0D19-410D-9F6C-01C14F8F0138 Q33638440-DF3F86AE-43C9-48E1-AB2A-1A0C96B448FE Q33677947-CE23A6A0-9ECB-4A3B-BE9F-8B8DE1C43DA4 Q33697616-EFF519B0-5F70-413A-8DF1-1724B0978403 Q33698123-C1A854C0-570E-4A85-8538-6968BD8B23C6 Q33713769-9D17D0AE-A73E-46BA-A4C2-32889AC4818F Q33720720-2C1D79A1-797F-46E1-8F8B-5B0A2920B7FE Q33746289-EC2CC683-B5E7-4AFD-AB73-3A5721AFBB20 Q33763107-CF6F6B32-40BA-467B-97BC-9A9D67FD1F5F Q33782744-F5633BC9-EB21-4316-B5D3-16FA35A154F9 Q33854486-38E3DC49-6EC5-4C30-BFC0-08857C3C771C Q33858257-7AF7349B-7DE6-4262-8BF8-224E0BE9273F Q33870715-1F333BB0-4046-49DA-BF37-2A16664E0A79 Q33893135-355B7308-8DF1-4BF1-B5D0-991C5DD915A3 Q33938412-93787511-069A-4136-B83E-2795089DDF60 Q33943887-2378AB8A-6206-48BF-8FB7-22A68FD5CD79 Q33985590-6171158A-8AC1-4190-88A8-CDEF8A576A24

P2860

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

http://www.wikidata.org/entity/Q45879717

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@en

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@nl

type

label

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@en

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@nl

prefLabel

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@en

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS.

@nl

P1433

Q45879717-3883F90F-4B68-4E80-B3C1-A8848EBCDF62

P1476

Q45879717-464674BF-A6E0-48D9-8FEC-C2346D226733

P2093

Q45879717-08A1B31D-48F1-4D09-8137-723B8BC90DCF

Q45879717-10CA3FD4-1711-410E-9125-48AB94201ADE

Q45879717-11257952-D177-4E1A-9703-374C656B0A3D

Q45879717-2B39C28E-554E-480A-AA3F-B80707CA1370

Q45879717-2BFE1D66-3E53-4D76-8495-F86D3C0E39CB

Q45879717-3B9F3486-6571-4EA6-BF1D-6C01BC4D7946

Q45879717-4D098668-0A67-4CE5-95FB-FEB91BCCF7C6

Q45879717-5358485F-66CF-40E3-B8EC-CE15C9ABCA22

Q45879717-58DD1147-EF97-4C3E-AE48-F7D74544AE2D

Q45879717-6337FBFB-A736-465A-986F-BCBA298AA3DD

P2860

Q45879717-00C8D0DD-490D-4BD8-A164-E44C78AE87D5

Q45879717-01E9557F-7D15-49FD-8A45-28DEA9796EF6

Q45879717-04E447CC-F119-43BC-8484-34F819D36C07

Q45879717-192548B8-AE5F-4B1C-B285-FA4AF3EE61C8

Q45879717-1E7E77AE-0655-4359-9448-ED1B261328DF

Q45879717-22B0DAE3-2675-41D9-87FA-259CEE58D813

Q45879717-29F049BC-45B8-4D51-B49C-28D7CEDE3E19

Q45879717-2A106AE0-6316-456C-9F8C-E95A93E75300

Q45879717-55D31538-DC7B-41A2-B10C-843EE1A89B6D

Q45879717-5EB9DAE2-571E-4B39-ABA4-3A2EC37B31D9

P2888

Q45879717-D11609D6-78D9-4488-8D42-870EC1914AC3

P304

Q45879717-2446F341-7911-4425-B028-1ED66C8C03D9

P31

Q45879717-EEE7B7AD-8ECF-43F6-8D37-A48F492C4924

P356

Q45879717-2C211ADA-4AAB-4152-8EA7-3C9EE8D6A443

P407

Q45879717-BA5B9040-C329-4445-AE07-3AFE5FADCA54

P433

Q45879717-30BE35C1-BBBE-4D5F-BA75-72EC2ACF2225

P478

Q45879717-2905A096-50F2-4B41-87DF-FA5453BEA682

P50

Q45879717-06297C3B-EF85-4718-A6BE-C1612684A963

Q45879717-0EC11A05-C113-4B47-8ACB-B16B94BD70FE

Q45879717-33FA01E0-B77E-470E-996F-9D9E1ACDDE16

Q45879717-4D880E09-7EC4-4316-8A8A-D1007817C53F

Q45879717-CDEE843B-DF16-4C15-9736-3D060D391F03

Q45879717-FE0DC502-4537-478A-A7DE-E6C35C0B8463

P577

Q45879717-747569F2-1AA3-4F1C-8B9F-F5B73A64F4B3

P5875

Q45879717-69142002-F0A8-41AC-86D2-C64993C261CB

P6179

Q45879717-A51848A2-D9A1-486F-96E8-BAE4C3252114

P698

Q45879717-C0FC3B8E-F767-419C-ABF4-F2EE6C77794C

P921

Q45879717-82076D11-E6ED-4DCC-954E-C8C4C892C468

P356

P1433

Nature Neuroscience

P1476

Treatment of motoneuron degene ...... of VEGF in a rat model of ALS

@en

P2093

Christoph Schmitz

http://www.w3.org/2001/XMLSchema#string

David Manka

http://www.w3.org/2001/XMLSchema#string

Diether Lambrechts

http://www.w3.org/2001/XMLSchema#string

Désiré Collen

http://www.w3.org/2001/XMLSchema#string

Hideyasu Oh

http://www.w3.org/2001/XMLSchema#string

Kristel Vermeulen

http://www.w3.org/2001/XMLSchema#string

Maria De Mol

http://www.w3.org/2001/XMLSchema#string

Maria-Paz Moreno-Murciano

http://www.w3.org/2001/XMLSchema#string

Mieke Dewerchin

http://www.w3.org/2001/XMLSchema#string

Nico Mertens

http://www.w3.org/2001/XMLSchema#string

P2860

The biology of VEGF and its receptors

The GDNF family: signalling, biological functions and therapeutic value

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches.

Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Location, location, location: a spatial view of neurotrophin signal transduction.

Mutant mouse models of insulin-like growth factor actions in the central nervous system.

Recent advances in amyotrophic lateral sclerosis research.

P2888

P304

85-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NN1360

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Philip Van Damme

Ludo Van Den Bosch

Edward M. Conway

Erik Storkebaum

P577

2004-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8159521

http://www.w3.org/2001/XMLSchema#string

P6179

1015614352

http://www.w3.org/2001/XMLSchema#string

P698

15568021

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis